Binnopharm Group To Acquire Ciprolet and Levolet brands from Dr. Reddy’s

0 89

Binnopharm Group, a Sistema Group company, and Dr. Reddy’s Laboratories Ltd., an integrated global pharmaceutical company, today announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy’s in Russia, Uzbekistan, and Belarus through its affiliate Joint Stock Company ‘Alium.’ The range comprises pills, infusion solutions, and ocular drops, among other dosage forms.

“The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets,”

Rustem Muratov, CEO of the Binnopharm Group said.

“Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key focus therapy areas of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, pediatrics, and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t Wait’,”

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), said. 

Dr. Reddy’s will continue to provide the product to Binnopharm Group during the transition phase to assure market availability.

Leave A Reply

Your email address will not be published.